EGFR and neoplasm: identified that QSOX1 (Quiescin sulfhydryl oxidase 1) enhanced sorafenib-induced ferroptosis by promoting the ubiquitination degradation of EGFR and inhibiting EGFR activation and thus inhibiting NRF2, providing QSOX1 as a new candidate target for a sorafenib-based combination therapy in advanced hepatocellular carcinoma or EGFR-dependent tumor types (136).